Literature DB >> 6541532

Methotrexate-related deaths in patients previously treated with cis-diamminedichloride platinum.

N Haim, A Kedar, E Robinson.   

Abstract

Among 106 patients treated with conventional-dose methotrexate (MTX) following prior therapy with cis-diamminedichloride platinum (CDDP), six died with clinical manifestations of MTX toxicity. Death occurred 6-13 days after the administration of 20-50 mg/m2 MTX. Toxicity included severe stomatitis and myelosuppression, which appeared in all six patients, skin rash in five, and diarrhea in four. Renal failure appeared in five cases and hepatic toxicity in four. All these patients had received MTX earlier without developing any serious toxicity. At the time of the last MTX administration, all had normal blood counts and also normal kidney and liver function tests. Prior therapy with CDDP may be responsible for this relatively high incidence of MTX-related deaths.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6541532     DOI: 10.1007/bf00269034

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  The synergistic effect of salicylates on methotrexate toxicity.

Authors:  M A Mandel
Journal:  Plast Reconstr Surg       Date:  1976-06       Impact factor: 4.730

2.  New "rescue" with massive doses of citrovorum factor for potentially lethal methotrexate toxicity.

Authors:  I Djerassi; J S Kim; N Nayak; H Ohanissian; S Adler; S Hsieh
Journal:  Cancer Treat Rep       Date:  1977-07

3.  Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.

Authors:  D D Von Hoff; J S Penta; L J Helman; M Slavik
Journal:  Cancer Treat Rep       Date:  1977-07

4.  Clinical pharmacology of methotrexate.

Authors:  B A Chabner; R C Donehower; R L Schilsky
Journal:  Cancer Treat Rep       Date:  1981

5.  Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability.

Authors:  D A Keefe; R L Capizzi; S A Rudnick
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

Review 6.  The clinical pharmacology of methotrexate: new applications of an old drug.

Authors:  W A Bleyer
Journal:  Cancer       Date:  1978-01       Impact factor: 6.860

7.  Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man.

Authors:  M Dentino; F C Luft; M N Yum; S D Williams; L H Einhorn
Journal:  Cancer       Date:  1978-04       Impact factor: 6.860

  7 in total
  5 in total

1.  Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer.

Authors:  Erin Dombrowsky; Bhuvana Jayaraman; Mahesh Narayan; Jeffrey S Barrett
Journal:  Ther Drug Monit       Date:  2011-02       Impact factor: 3.681

Review 2.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 4.  Clinical management of cytotoxic drug overdose.

Authors:  L L Thomas; M J Mertens; A E von dem Borne; C J van Boxtel; C H Veenhof; E P Veies
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jul-Aug

Review 5.  Antineoplastic agents. Drug interactions of clinical significance.

Authors:  E van Meerten; J Verweij; J H Schellens
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.